A Trial To Evaluate The Efficacy And Safety Of Multiple Combination Therapies In Participants With Chronic Hepatitis B

Prior treatment

• History of having received (in the last 6 months) or currently receiving any systemic antineoplastic (including radiation) or immunosuppressive (including biologic immunosuppressors) or immune modulating treatment.
• Currently taking, or have received within 3 months of Day 1, systemic corticosteroids.
• Previous treatment with an investigational agent for Hepatitis B (HBV) within 6 months prior to screening.

Other illness

• Co-infection with other pathogens such as Hepatitis A, C, D and E or Human Immunodeficiency Virus (HIV).
• History of cirrhosis or current evidence of significant liver fibrosis or cirrhosis or decompensated liver disease.
• History of or suspicion of Hepatocellular Carcinoma (HCC).
• Thyroid disease poorly controlled on prescribed medications or clinically relevant abnormal thyroid function tests.
• Clinically significant disease other than CHB that, in the opinion of the Investigator, makes the participant unsuitable for the study.
• Pre-existing cardiac disease that in the opinion of the investigator would increase the risk for the participant to take part in the study.
• History of alcohol abuse and/or drug abuse within one year of randomization.

Other

• Pregnant or lactating women.
• Electrocardiogram (ECG) with clinically significant abnormalities.

• Body mass index between 18 and 32 kg/m2 inclusive.
• Participants with Chronic Hepatitis B (CHB) infection (HBsAg positive for \>=6 months) who are on established NUC (entecavir or tenofovir alafenamide/disoproxil fumarate) monotherapy for \>=12 months, having received the same NUC therapy for \>=3 months prior to screening.
• HBV DNA below the lower LLOQ or \< 20 IU/mL for \> 6 months prior to screening and confirmed at screening.
• Alanine transaminase (ALT) \<=1.5 x upper limit of normal (ULN) for \> 6 months prior to screening and confirmed at screening.
• Female Participants: Eligible to participate if she is not pregnant, not breastfeeding and agrees to remain abstinent (refrain from heterosexual intercourse) or use highly effective contraceptive methods.
• Male Participants: During the treatment period and for at least 6 months after the final dose of study treatment, agrees to remain abstinent (refrain from heterosexual intercourse), use contraceptive measures and refrain from donating sperm.